Abstract

Glaukos will report quarterly results on April 29, 2026 Post Market; consensus points to accelerating top-line growth with improving EPS loss, while investors focus on gross margin resilience and uptake in glaucoma and corneal health portfolios.

Market Forecast

- For the current quarter, the market projects Glaukos revenue at 136.92 million US dollars with an estimated year-over-year increase of 33.57%, an EBIT loss of 17.35 million US dollars with a forecast year-over-year improvement of 14.13%, and an EPS loss of -0.273 with a year-over-year improvement of 21.52%. - Based on recent trend data, gross profit margin is tracked at 77.80%; net profit margin prints as negative, and consensus expects adjusted EPS loss to narrow year over year. - The main business remains glaucoma devices with an expanding corneal health contribution, as product uptake and channel execution drive volume growth. - The segment with the largest near-term potential is glaucoma, which generated 421.07 million US dollars over the latest disclosed period; corneal health contributed 86.37 million US dollars, with both categories benefitting from broader adoption and procedure volume expansion.

Last Quarter Review

- Glaukos reported revenue of 143.12 million US dollars, gross profit margin of 77.80%, GAAP net loss attributable to shareholders of 134.00 million US dollars, a net profit margin of -93.39%, and adjusted EPS of -0.28, reflecting a year-over-year improvement of 30.00%. - Quarterly momentum featured outperformance versus top-line consensus, highlighting sustained demand across core product lines and disciplined pricing. - Main-business highlights: glaucoma revenue reached 421.07 million US dollars and corneal health revenue was 86.37 million US dollars in the latest breakdown; both were supported by strong utilization trends and increased procedure penetration.

Current Quarter Outlook (with major analytical insights)

Glaucoma portfolio trajectory

The glaucoma portfolio is expected to remain the primary revenue engine this quarter, building on strong utilization trends from prior periods. Unit demand should benefit from procedural throughput recovery, continued surgeon onboarding, and deeper penetration into cataract-combo use cases where micro-invasive glaucoma surgery is well established. Management emphasis on training, account coverage, and evidence generation supports stable pricing and volume growth. The key watch items are supply continuity and competitive launches in minimally invasive glaucoma interventions that could influence share capture in select accounts. Given the revenue base of 421.07 million US dollars in the latest mix snapshot, incremental procedure growth of mid- to high-teens could translate into meaningful contribution toward the 136.92 million US dollars quarterly consensus. Margin sensitivity remains limited by product mix, with gross margin historically resilient near the high-70s; however, any promotional activity or higher mix of newer SKUs could modulate realized margins.

Corneal health expansion

Corneal health is positioned as a secondary but faster-growing pillar, supported by broader awareness, improving reimbursement familiarity, and expanded indications across target geographies. With the latest revenue base of 86.37 million US dollars in the segment breakdown, a continued double-digit growth trajectory can bolster total company growth and diversify the revenue mix beyond glaucoma. Commercial focus on expanding referral networks and optimizing patient flow should help sustain volume gains without undue pressure on pricing. Operational leverage could be gradual, as scale benefits offset ongoing investments in market education and clinical support. For the quarter, we expect corneal health to contribute a modestly higher share of revenue than prior-year periods, aiding the consensus call for a 33.57% year-over-year increase in total revenue.

Variables shaping stock performance this quarter

Share performance into and after the print is likely to hinge on three factors: revenue growth durability, the cadence of EPS loss narrowing, and gross margin resilience. The revenue consensus at 136.92 million US dollars embeds robust year-over-year growth; upside risk would most likely come from stronger-than-expected procedure volumes in glaucoma and steady expansion in corneal health. On profitability, the forecast EPS loss of -0.273 implies year-over-year improvement of 21.52%, reflecting operating leverage as fixed cost absorption improves; investors will look for signals that spending discipline remains intact while supporting growth initiatives. Gross margin commentary will be closely scrutinized, as product mix and any early commercialization of newer offerings could nudge margin around the high-70s area; even minor deviations may influence post-report trading. Execution clarity on supply chain, channel inventory, and competitive dynamics in micro-invasive glaucoma surgery will round out the near-term narrative.

Analyst Opinions

The prevailing institutional stance skews bullish, with a clear majority emphasizing above-trend revenue growth and ongoing loss reduction into April 29, 2026. Recent analyst commentary highlights three consistent points: resilient demand in glaucoma procedures, accelerating contribution from corneal health, and high-70s gross margin durability that supports operating leverage. Several well-followed sell-side teams have reiterated positive views on the name, pointing to consensus revenue at 136.92 million US dollars and an improving EBIT profile with a projected loss of 17.35 million US dollars, as signs that the growth algorithm remains intact. The bullish majority contends that upside could materialize if procedure momentum in glaucoma exceeds expectations and if operating expenses track within plan, allowing EPS to narrow more than the -0.273 consensus. Overall, the dominant view expects a constructive setup driven by strong top-line expansion, sticky surgeon adoption, and steadier unit economics, while acknowledging that any unexpected mix-driven pressure on gross margin would be a key swing factor.